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Flupirtine (FLU) is a non-opioid analgesic drug with no antipyretic or antiphlogistic effects 27 
labelled for humans. It does not induce the side effects associated with the classical drugs used as 28 
pain relievers (NSAIDs and opioids) in human beings. The aim of this study was to evaluate the 29 
pharmacokinetic profiles of FLU after IV and PO administration in healthy donkeys. Six Amiata 30 
breed adult jennies were randomly assigned to two treatment groups using an open, 2 x 2 Latin-31 
square cross-over study design. Group 1 (n = 3) received a single dose of 1 mg/kg of FLU injected 32 
IV into the jugular vein. Group 2 (n = 3) received FLU (5 mg/kg) via nasogastric tube. The wash 33 
out period was 1-week. Blood samples (5 mL) were collected at 0.083, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 34 
6, 8, 10, 24, 36 and 48 h and plasma was then analysed by a validated HPLC method. No adverse 35 
effects were noticed in either administration group. After IV and PO administrations, FLU was 36 
detectable in plasma for up to 24 h. The mean elimination half-life was longer after PO (10.81 h) 37 
than after IV (0.90 h) administration. The clearance was fast and the AUC was small, findings 38 
consistent with a low oral bioavailability of about 20%. The pharmacokinetic trend of FLU in 39 
donkeys was different from those earlier reported in cats and dogs. Further studies are needed to 40 
understand if this active ingredient may be used in donkeys. 41 
 42 
 43 
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 47 
Flupirtine (FLU) is an aminopyridine drug (ethyl {2-amino-6-[(4-fluorobenzyl) amino] 48 
pyridin- 3-yl}carbamate) approved in Europe in 1984 for treatment of a wide range of pain states in 49 
human beings [1]. Flupirtine is a centrally acting analgesic with a mechanism of action unlike that 50 
of opiates and NSAIDs. It is active with a favourable tolerability and with no antipyretic or 51 
antiphlogistic effects in humans [2]. Flupirtine is the first drug to be recognised in the unique class 52 
of ‘Selective Neuronal Potassium Channel Openers’ (SNEPCO) [3]. It interacts with the G-protein-53 
regulated, Inwardly Rectifying K+ channels (GIRKs), a novel family of K+ channels distinct from 54 
the voltage-dependent ones. They are regulated by neurotransmitters and are expressed in different 55 
parts of the brain. Flupirtine activates GIRKs and stabilizes the membrane resting potential by 56 
activating potassium channels KCNQ and thus generating a neuronal hyperpolarizing current (M-57 
current). The increased M-current due to the action of FLU translates to decreased neuronal 58 
excitability [4]. Moreover, FLU inhibits the NMDA receptor indirectly by acting as an oxidizing 59 
agent at the redox site of the NMDA receptor, maintaining the Mg2+ block on the NMDA receptor 60 
[2]. 61 
 62 
In line with its mechanism of action promoting neuronal rest, it has proven useful in 63 
conditions involving neuronal hyperexcitability such as chronic pain (non-malignant and 64 
malignant), migraine and neurogenic pain [5-10]. Furthermore, its effect as a muscle relaxant 65 
represents added value in painful conditions associated with increased muscle tension, such as 66 
musculoskeletal back pain, myofascial pain and tension headaches [1,6,11-13]. Flupirtine has also 67 
been shown as beneficial in the short-term treatment of acute to moderate pain such as 68 
postoperative pain, trauma and dysmenorrhoea [14]. The approved indications of FLU differ 69 
between countries but mainly include the clinical management of musculoskeletal pain, 70 
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and chemical burns) and pain associated with cancer [15-16]. It has possibly not been used to its full 72 
potential as an analgesic in the first decade of the 21st century, but in recent years, there has been a 73 
resurgence in FLU use after discovery of its powerful-synergistic effects when used with opioids 74 
[4,17-18] in addition to its properties when used alone [19].  75 
 76 
While there is a substantial body of evidence on the efficacy of FLU in humans, only a single 77 
study on the analgesic effect of FLU in laboratory animals is present in the literature [20] and its 78 
pharmacokinetic profiles in cats [21] and dogs [22] have been recently described. Advanced studies 79 
(phase III) in dogs and horses are ongoing in the USA 80 
(http://www.kindredbio.com/#!pipeline/c1ktj). As no data on the pharmacokinetic profiles of FLU 81 
in donkeys exists, the aim of this study was to evaluate its pharmacokinetic after IV and PO 82 
administration in this species.  83 
 84 
2 Materials and methods 85 
2.1 Chemical and reagents 86 
Pure FLU maleate salt and the Internal Standard trazodone (IS) powders (both >99.0% purity) 87 
were supplied by Sigma-Aldrich (St. Louis, MO, USA). HPLC grade acetonitrile (ACN), methanol 88 
(MeOH), dichloromethane (CH2Cl2) and ethyl acetate (AcOEt) were purchased from Merck 89 
(Darmstadt, Germany). Ammonium acetate (AcONH4) was purchased from Carlo Erba (Milano, 90 
Italy). Deionised water was produced by a Milli-Q Milli-pore Water System (Millipore, MA, USA). 91 
All other reagents and materials were of analytical grade and supplied from commercial sources. 92 
The LC mobile phase was filtered through 0.2 µm cellulose acetate membrane filters (Sartorius 93 
Stedim Biotech S.A., Aubagne Cedex, France) with a solvent filtration apparatus. 94 
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 95 
2.2 Animal and experimental design 96 
The subjects were six Amiata jennies, aged 4 to 7 years and weighing 150 to 210 kg. The 97 
jennies were determined to be clinically healthy on physical examination, serum chemistry and 98 
haematological analyses. Animals were evaluated daily (for 1 week) for visible adverse effects by 99 
specialized personnel. Animal care and handling was performed according to the provision of the 100 
EC council Directive 86/609 EEC and also according to Institutional Animal Care and Use 101 
directives issued by the Animal Welfare Committee of the University of Camerino, which approved 102 
the study protocol. 103 
 104 
Donkeys were randomly assigned to two treatment groups (six slips of paper marked with the 105 
numbers 1 to 6 in a box), using an open, single-dose, two-treatment, two-phase, paired, cross-over 106 
design (2 x 2 Latin-square). All subjects were fasted for 12 h overnight before each experiment.  107 
In both periods, a jugular catheter was placed for the purpose of blood sample collection. In 108 
addition, in the IV group, a second jugular catheter was placed in the contralateral jugular vein for 109 
intravenous drug administration. Placement of the jugular catheter occurred approximately 12 h 110 
prior to the start of the investigation. Donkeys were restrained by a handler during the process of 111 
catheter placement. The area over the jugular vein was clipped and surgically prepared with 112 
alternating scrubs of 70% isopropyl alcohol and povidone iodine. The catheter site was infiltrated 113 
with 1 mL of 2.5% lidocaine/prilocain injection given subcutaneously (EMLA, AstraZeneca, Milan 114 
Italy). Using sterile technique, an 18 G x 55 mm intravenous catheter (Picco, Pulsion, Milan Italy) 115 
with injection plug was inserted into the vein and sutured to the skin using #3 nylon suture 116 
(Vetsuture, Sanitalia, Napoli, Italy). Catheter patency was maintained by flushing with 2 mL of a 117 
heparin saline solution containing ten international units heparin sodium/mL saline (Heparin 118 
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to sample collection.  120 
 121 
During the first phase, each donkey in group 1 (n = 3) received a single dose of 1 mg/kg of 122 
FLU (Katadolon® 100 mg/3 mL vials, FLU D-gluconate AWD Pharma, Radebeul, Germany) 123 
injected IV at a flow rate of 3 mL/min. Group 2 (n = 3) received a dose of 5 mg/kg via the PO route 124 
(Efiret® 100 mg hard capsules, FLU maleate, Meda Pharma S.p.A. Milano, Italy). The oral 125 
formulation of FLU was given to all animals via nasogastric tube and consisted of capsules in 300 126 
mL of distilled water. After administration, the nasogastric tube was rinsed with 300 mL of distilled 127 
water to ensure complete delivery of the drug into the stomach. A 1-week wash out period was 128 
observed between the phases, then the groups were rotated and the experiment was repeated. Blood 129 
samples (5 mL) were collected at 0.083, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, 24, 36 and 48 h after 130 
administration of FLU and placed in collection tubes containing lithium heparin. Samples were 131 
immediately centrifuged at 2000 g (10 min), and the harvested plasma was stored at -20 rC until 132 
use within 30 days from collection.  133 
 134 
2.3 High performance liquid chromatography 135 
The analytical method was based on a previous method validated in dog plasma [22]. In brief, 136 
the HPLC system was an LC Jasco (Como, Italy) consisting of quaternary gradient system (PU 980) 137 
and an in line multilambda fluorescence detector (FP 1520). The chromatographic separation assay 138 
was performed with a Luna C18(2) analytical column (250 mm × 4.6 mm inner diameter, 5 µ 139 
particle size [Phenomenex, Bologna, Italy]) preceded by a security guard column with the same 140 
stationary phase (C18(2) [Phenomenex, Bologna, Italy]). The system was maintained at 25◦C. The 141 
mobile phase consisted of ACN:AcONH4 (20 mM) solution, pH 6.8 (60:40, v/v) at a flow rate of 1 142 
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mL/min. Excitation and emission wavelengths were set at 323 and 370 nm, respectively. The 143 
elution of the substances was carried out in isocratic mode. 144 
 145 
2.3.1 Sample extraction 146 
The procedure was performed in a 15 mL polypropylene vial. A 500 µL aliquot of plasma was 147 
added to 100 µL of IS (100 µg/mL) and vortexed for 60 sec. Four mL of AcOEt:CH2Cl2 (7:3 v/v) 148 
was added, then the sample was vortexed (30 sec), shaken (100 osc/min, 10 min) and centrifuged at 149 
3000 g for 10 min at 10° C. Three mL of the supernatant was collected in a separate clean vial. The 150 
organic phase was evaporated under a gentle stream of nitrogen at 40 °C and reconstituted with 500 151 
µL of the mobile phase. Twenty µL of this latter solution was injected onto the HPLC-FL. 152 
 153 
2.4 Pharmacokinetic evaluation 154 
Flupirtine plasma concentration vs. time curves were modeled for each subject using a mono- 155 
or a two-compartment open model [23]. Comparison between competing models was made using 156 
the residual plots, visual inspection of the goodness of fit curves and the Akaike’s information 157 
criterion. The pharmacokinetic calculations were carried out using WinNonLin v 5.3.1 (Pharsight). 158 
The PO bioavailability was calculated from the ratio of the areas under the plasma FLU 159 
concentration curve after PO and IV administration, respectively, indexed to their respective dose: 160 
F(%) = (AUCPO x DoseIV)/(AUCIV x Dose PO) x 100  161 
 162 
2.5 Statistical analysis 163 
Pharmacokinetic variables were evaluated using the Student’s t test to determine statistically 164 
significant differences between the treatment groups. Both pharmacokinetic parameters and FLU 165 
plasma concentrations are presented as means ± standard deviation (normality tested by Shapiro-166 
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experiments, differences were considered significant if P < 0.05. 168 
 169 
3 Results 170 
The HPLC method was re-validated using donkey plasma. Briefly, FLU was linear (r2 >0.99) 171 
in the range 10-1500 ng/mL. Limit of detection and quantification were 3 and 10 ng/mL, 172 
respectively. When samples exceeded the upper limit of the range, they were re-analysed after 173 
appropriate dilution. The intraday repeatability was measured as coefficient of variation and was 174 
lower than 4.9 %, whereas accuracy, measured as closeness to the concentration added on the same 175 
replicates, was lower than 7.1 %. 176 
 177 
No behavioral changes or alterations in health parameters were observed in the IV and PO 178 
groups of animals during or after (up to 7 days) the drug administration. Physiological signs and 179 
parameters were normal. 180 
 181 
A bi-compartmental model best fitted the plasma concentrations after IV and PO 182 
administrations in all the six donkeys. Two-compartment with bolus input and first-order output, 183 
micro-constants as primary parameters was used for the IV administration while a first-order input, 184 
first-order output, no lag time and micro-constants as primary parameters was used for the PO 185 
administration. The average plasma concentration vs. time curves after both the administrations are 186 
reported in Fig. 1. After IV administration the data at the first collection time point was extremely 187 
variable (range 1508-13296 ng/mL). Flupirtine was detectable in plasma up to 24 h, then the drug 188 
concentrations dropped down to the LOQ of the method (10 ng/mL). After oral administration (5 189 
mg/kg), the FLU plasma concentrations were quite variable, and were detectable over the same 190 
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range of time. The average Cmax (936 ng/mL) was shown at a Tmax of 0.33 h. The oral 191 
bioavailability (F%) was 19.75 ± 12.16 %. The half-life of elimination (Beta_HL) value was 10 192 
times higher in the PO compared to the IV group. The complete pharmacokinetic parameters are 193 
reported in Table 1.  194 
 195 
4 Discussion 196 
Flupirtine is a centrally acting, non-opioid analgesic that is available in a number of European 197 
countries for the treatment of a variety of pain states [15]. The therapeutic benefits seen with FLU 198 
relate to its unique pharmacological properties. Recently its potential for use in veterinary medicine 199 
has been explored [24]. Preclinical studies showed that FLU was more effective than paracetamol 200 
and as effective as pentazocine in the electrostimulated pain test in mice [25]. Flupirtine 201 
significantly prolonged the latency of the tail-flick test in rats [26]. Flupirtine produced an efficacy 202 
profile superior to that of tramadol for cancer-associated pain in rats and humans [4,5]. Flupirtine 203 
produced a significant increase in morphine antinociception when the two drugs were administered 204 
in combination in different rat models of pain [17,18]. If the opioid sparing effect is also evident in 205 
donkeys, this active ingredient could play an important role in combinatorial analgesic therapy in 206 
order to avoid moderately high regimens of opioids. Flupirtine might also be an attractive 207 
alternative for patients with a history of adverse drug reaction to NSAIDs [27]. Indeed it does not 208 
induce the gastrointestinal and renal side effects evoked by classical NSAIDs and COX-2 selective 209 
inhibitors [28].  210 
 211 
Allometric scaling is an approach for dosage selection that can be used in the absence of 212 
either species-specific pharmacokinetic data or prior drug experience in the target species [29]. In 213 
the present study, an evidence-based approach rather than an allometric calculation of the dose was 214 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPTpreferred. Both the approaches share the assumption that species differences in pharmacodynamics 215 
are clinically negligible. The oral dose administered in the present study (5 mg/kg) was about 3 216 
times higher than the minimum dose reported in human clinical practice (100 mg/subject/day). 217 
However, it was still within the recommended human clinical range (100-400 mg/subject/day) [15]. 218 
The rationale for oral dose selection of 5 mg/kg was based on earlier preclinical studies in dogs and 219 
cats. The ED50 of FLU after oral administration in the electrical tooth pulp stimulation test in dogs 220 
and cats was 3.5 mg/kg [25] and 3 mg/kg [20], respectively. Additionally, recent pharmacokinetic 221 
studies carried out with this dose regimen did not show any adverse effects after oral administration 222 
[21,22]. A recent study also indicated that the theoretical effective oral dose of FLU in horses is 2.6 223 
mg/kg [30]. However, as according to earlier studies donkeys require higher drug dose than horses 224 
[31-35], a 5 mg/kg oral dose was preferred. 225 
 226 
In variance to the PO route, 5 mg/kg of FLU administrated IV produced some adverse effects 227 
in dogs [22]. In the present study the IV dose was reduced to 1 mg/kg to minimise potential adverse 228 
effects. No side effects were visible in donkeys even though the highest plasma concentrations were 229 
higher than those detected in horses administered with the same IV dose (1mg/kg), where only 230 
some mild and transient adverse effects were visible [30]. However, FLU as an analgesic drug is 231 
expected to be administered in multiple doses. Toxicity might be potential at multiple dose regimen 232 
and should be tested in further studies. 233 
 234 
No experimental information about the minimal effective concentration in humans or animal 235 
species is available for FLU. A recent study has calculated in silico that the theoretical plasma 236 
effective concentration of FLU in horses is 178 ng/mL [30]. If this data also holds true in donkeys, 237 
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administrations, FLU plasma concentrations are below that value after 1.5 hours.  239 
 240 
Flupirtine is a water-soluble compound in the form of maleate salt (pKa 5.3) that is rapidly 241 
absorbed from the human gastro intestinal tract [36]. The Tmax found in this study (0.33 h) was 242 
shorter than the Tmax reported for dogs (1.42 h), humans (range 1.6-1.8 h), and cats (2.78 h) 243 
showing a faster rate of absorption of the drug in donkeys. A number of factors may be responsible 244 
for this difference: the large variation in this parameter in the donkey, different absorption, gastric 245 
emptying, transit time or other species-specific factors  246 
 247 
Following PO administration of FLU, donkeys showed mean terminal plasma elimination 248 
half-lives in between those reported in cats (13.6 h) and dogs (7.1 h) [21-22]. The average clearance 249 
value in donkeys was much larger than those reported in dogs (604 mL/h/kg) and in cats (195 250 
mL/h/kg) [21-22]. Interestingly, oral bioavailability (F%) in donkeys has also been shown as half of 251 
that reported for cats and dogs. This difference might be due to both larger clearance and rapid drug 252 
metabolism. Large differences in F% between humans and animals and between animals 253 
(carnivorous vs. herbivorous) have previously been demonstrated, indicating that F% values derived 254 
in an animal species cannot always be extrapolated to humans or other animal species [37]. 255 
Remarkably, a recent study has shown an oral F% of about 70% in horses [30]; this difference 256 
between the equine species is in line with earlier studies reporting a significantly reduced drug oral 257 
F% in donkeys compared to horses [31-35]. 258 
 259 
 260 
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This is the first study on FLU in donkeys. The pharmacokinetic profiles of FLU in donkeys 262 
were different compared to FLU disposition in humans, cats and dogs. Donkeys have shown a large 263 
clearance and a low oral bioavailability, which are consistent with relatively low plasma drug 264 
concentration profiles if compared to other animal species. Further studies need to be undertaken to 265 
confirm the pharmacokinetic profile and to evaluate the analgesic effect in this animal species. 266 
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administrations in healthy donkeys (n = 6) 397 
 398 
      
  
  
  
        IV     PO 
Parameters Units   Mean   SD   Mean    SD 
AUC hr*ng/mL   1867.97 ± 1138.93   1454.69 ± 748.9953 
K01_HL hr   / ± /   0.21648 ± 0.097415 
K10_HL hr   0.13213   0.1005   0.49594 ± 0.186669 
Alpha 1/hr   11.9077 ± 6.27947   2.85026 ± 0.847724 
Beta 1/hr   1.35979 ± 0.60358   0.08926 ± 0.048583 
Alpha_HL hr   0.0869 ± 0.07795   0.25886 ± 0.063732 
Beta_HL hr   0.9065 ± 1.13075   10.8139 ± 7.215173 
Cmax ng/mL   / ± /   936.861 ± 512.7385 
Tmax hr   / ± /   0.33537 ± 0.1168 
CL‡ mL/hr/kg   679.419 ± 312.95   4812.8 ± 3721.237 
V2‡ mL/kg   297.564 ± 428.636   27870.9 ± 22017.29 
AUMC hr*hr*ng/mL   702.329 ± 378   / ± / 
MRT hr   0.52 ± 0.51   / ± / 
V1‡ mL/kg   157.81 ± 179.621   3367.13 ± 2777.976 
K01 1/hr   / ± /   4.63402 ± 4.202936 
K10 1/hr   7.91 ± 5.62956   1.66127 ± 0.922205 
K12 1/hr   3.16 ± 1.84219   1.10169 ± 0.443344 
K21 1/hr   2.19465 ± 1.03867   0.17657 ± 0.130243 
F% % 
          19.75 ± 12.16 
                    
 399 
AUC, area under the plasma concentration–time curve; K01_HL, half-life of the absorption phase; K10_HL, half-life of 400 
the elimination phase; Alpha, rate constant associated with distribution; Beta, rate constant associated with elimination; 401 
Alpha_HL, distribution half-life; Beta_HL, elimination half-life; Cmax, peak plasma concentration; Tmax, time of peak; 402 
CL, clearance; V2, volume of compartment 2; AUMC, area under the first moment curve; MRT, mean residue time; 403 
V1, volume of compartment 1; K01, absorption rate; K10, elimination rate from compartment 1; K12, rate of movement 404 
from compartment 1 to 2; K21, rate of movement from compartment 2 to 1; F%, bioavailability. ‡ For the oral 405 
administration these parameters are divided for their bioavailability. 406 
 407 
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ACCEPTED MANUSCRIPTFigure captions 410 
Fig. 1. Mean plasma concentrations of flupirtine vs. time curves following PO (5 mg⁄kg) (─●─) and 411 
IV (--○--) (1 mg⁄kg) administrations in healthy donkeys (n = 6). The window graph focuses on the 412 
FLU plasma concentrations detected in first 6h after treatment. Bars represent the standard 413 
deviations. 414 
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Highlights 
Flupirtine IV (1 mg/kg) and oral (5 mg/kg) administered, did not show any adverse effect in 
donkeys 
Flupirtine oral bioavailability was about quite low in donkeys (about 20%) 
The pharmacokinetics of flupirtine in donkeys is different from those earlier reported in cats and 
dogs 
